The following list contains links to publications and information on Ophthalmic Cyclosporine:

• Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.

• Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.

• Histologic characteristics and local cellular immunity of the gland of the third eyelid after topical ophthalmic administration of 2% cyclosporine for treatment of dogs with keratoconjunctivitis sicca.

• Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs.

• Treatment of keratoconjunctivitis sicca in dogs with cyclosporine ophthalmic ointment: a European clinical field trial.

• Microorganisms isolated from the corneal surface before and during topical cyclosporine treatment in dogs with keratoconjunctivitis sicca.

• Tear protein profiles vs. clinical characteristics of untreated and cyclosporine-treated canine KCS.

• A new perspective on canine keratoconjunctivitis sicca. Treatment with ophthalmic cyclosporine.

• Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops.

• Search PubMed for additional information on Ophthalmic Cyclosporine

• Research and Publications on KCS and Cyclosporine
  by RL Kaswan DVM, MS DACVO

KB Visions, Inc.
6787 Riverside Dr. NW
Atlanta, Georgia 30328
©2002 KB Visions, Inc. All rights reserved.